Plunkett Consulting has successfully assisted an Australian manufacturer lodge their first Conformity Assessment Application for Class IV in vitro diagnostics (IVD). This submission signifies a successful collaboration for the development of a Device Design dossier to demonstrate conformance with the Therapeutic Goods Administration (TGA) Essential Principles of Safety and Performance.
Contact us to discover how Plunkett Consulting can assist with navigating through the Australian regulatory system.
You might also like...
Accelagen facilitates LEDAGA Approval in Australia
We're pleased to be an integral part of the approval of LEDAGA® by TGA on behalf of the Australian office of Recordati Rare Diseases.
Read MoreAccelagen driving development of new candidate for COVID-19 Vaccine
Accelagen is excited to announce the initiation of a new COVID-19 vaccine trial, commencing in Melbourne on Tuesday 1st September!
Read MoreConformity Assessment Application
We've successfully assisted an Australian manufacturer lodge their first CAA.
Read More